PLGLB2抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P09809(PLGLB2 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P09809(PLGLB2 Antibody) at dilution 1/65. (Original magnification: ×200)    

  
  

The PLGLB2 antibody targets plasminogen-like protein B2 (PLGLB2), a member of the plasminogen-related protein family. PLGLB2 shares structural homology with plasminogen, a key enzyme in fibrinolysis and tissue remodeling, but lacks proteolytic activity due to mutations in its catalytic domain. It is primarily expressed in the liver and detected in various tissues, though its biological role remains incompletely understood. Research suggests PLGLB2 may modulate plasminogen activation pathways, potentially influencing processes like angiogenesis, inflammation, or tumor progression by competing for binding sites with plasminogen or related receptors.

PLGLB2 antibodies are critical tools for studying its expression patterns and functional mechanisms. They are utilized in techniques such as Western blotting, immunohistochemistry, and ELISA to quantify protein levels in physiological and pathological contexts. Elevated PLGLB2 levels have been observed in certain cancers, including colorectal and breast carcinomas, implicating its potential as a biomarker or therapeutic target. However, its precise role in disease pathogenesis requires further investigation. Commercial PLGLB2 antibodies are typically raised in rabbits or mice, with validation data ensuring specificity for research applications. Ongoing studies aim to clarify its interactions within the plasminogen system and its broader implications in health and disease.